Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
Launched by PFIZER · Aug 18, 2011
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Receipt of at least 1 dose of investigational product (etanercept) and participation for approximately 96 weeks in study 0881A1-3338 (B1801014)
- • Personally signed and dated informed consent document (and assent document, as applicable) indicating the subject (or legally representative/guardian) has been informed of all pertinent aspects of the study.
- Exclusion Criteria:
- Exclusion criteria for subject planning to continue investigational product:
- • withdrawal from investigational product in study 0881A1-3338 for any reason (safety or non-safety).
- • History of maliginancy other than squamous cell, basal cell carcinoma or cervical carcinoma in situ.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belgrade, , Serbia
Madrid, , Spain
Gent, , Belgium
Brussels, , Belgium
Praha 2, , Czechia
Paris, , France
Valencia, , Spain
Piestany, , Slovakia
Berlin, , Germany
Bremen, , Germany
Nis, , Serbia
Krakow, , Poland
Bydgoszcz, , Poland
Westmead, Sydney, New South Wales, Australia
Parkville, Melbourne, Victoria, Australia
Bucaramanga, Santander, Colombia
Brno, , Czechia
Praha 2, , Czechia
Paris, , France
Hamburg, , Germany
Saint Augustin, , Germany
Budapest, , Hungary
Chieti Scalo, , Italy
Riga, , Latvia
Riga, , Latvia
Vilnius, , Lithuania
Mexico, D.F., Mexico
Utrecht, , Netherlands
Oslo, , Norway
Warszawa, , Poland
Wroclaw, , Poland
Moscow, , Russian Federation
Saint Petersburg, , Russian Federation
Ljubljana, , Slovenia
Esplugues De Llobregat, Barcelona, Spain
Hamburg, , Germany
Madrid, , Spain
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials